PI3K pathway inhibitors approach junction

被引：44
|
作者：
Holmes, David
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2011年 / 10卷 / 08期
关键词：
D O I：
10.1038/nrd3527
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [41] Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
    Roudsari, Nazanin Momeni
    Lashgari, Naser-Aldin
    Momtaz, Saeideh
    Abaft, Shaghayegh
    Jamali, Fatemeh
    Safaiepour, Pardis
    Narimisa, Kiyana
    Jackson, Gloria
    Bishayee, Anusha
    Rezaei, Nima
    Abdolghaffari, Amir Hossein
    Bishayee, Anupam
    PHARMACEUTICS, 2021, 13 (08)
  • [42] Development of Inhibitors of the IGF-IR/PI3K/Akt/mTOR Pathway
    Hixon, Mary L.
    Paccagnella, Luisa
    Millham, Robert
    Perez-Olle, Raul
    Gualberto, Antonio
    REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 189 - 208
  • [43] Clinical development of PI3K/AKT pathway inhibitors in breast cancer.
    Derynck, Mika
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 22 - 22
  • [44] PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors
    Wolin, Edward M.
    CANCER LETTERS, 2013, 335 (01) : 1 - 8
  • [45] PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma
    Oh, Taemin
    Ivan, Michael E.
    Sun, Matthew Z.
    Safaee, Michael
    Fakurnejad, Shayan
    Clark, Aaron J.
    Sayegh, Eli T.
    Bloch, Orin
    Parsa, Andrew T.
    IMMUNOTHERAPY, 2014, 6 (06) : 737 - 753
  • [46] PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
    Wu, P.
    Hu, Y-Z
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) : 4326 - 4341
  • [47] Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors
    Friedman, L.
    Belvin, M.
    Le Couter, J.
    Lin, K.
    Robillard, L.
    Sampath, D.
    Stern, H.
    Vijapurkar, U.
    Ye, W.
    Plowman, G.
    EJC SUPPLEMENTS, 2008, 6 (12): : 71 - 71
  • [48] Genotype-based combinations of RAS/RAF and PI3K pathway inhibitors
    Banerji, U.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S7 - S7
  • [49] Volume scanning, a rational approach to covalent PI3Kα inhibitors.
    Borsari, Chiara
    Keles, Erhan
    McPhail, Jacob
    Schafer, Alexander
    Sriramaratnam, Rohitha
    De Pascale, Martina
    Gstaiger, Matthias
    Burke, John
    Wymann, Matthias P.
    CANCER RESEARCH, 2021, 81 (13)
  • [50] PI3K Pathway Inhibitors: What Have we Achieved and Future Directions
    Tabernero, J.
    Dienstmann, R.
    Cervantes, A.
    Brana, I.
    Alsina, M.
    Rodon, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S85 - S85
12345